Outlook Therapeutics (OTLK) Accumulated Expenses: 2015-2019
Historic Accumulated Expenses for Outlook Therapeutics (OTLK) over the last 5 years, with Sep 2019 value amounting to $4.6 million.
- Outlook Therapeutics' Accumulated Expenses rose 63.83% to $7.3 million in Q2 2020 from the same period last year, while for Jun 2020 it was $7.3 million, marking a year-over-year increase of 63.83%. This contributed to the annual value of $4.6 million for FY2019, which is 28.42% down from last year.
- Outlook Therapeutics' Accumulated Expenses amounted to $4.6 million in FY2019, which was down 28.42% from $6.5 million recorded in FY2018.
- Outlook Therapeutics' 5-year Accumulated Expenses high stood at $7.3 million for FY2017, and its period low was $4.6 million during FY2019.
- Over the past 3 years, Outlook Therapeutics' median Accumulated Expenses value was $6.5 million (recorded in 2018), while the average stood at $6.1 million.
- In the last 5 years, Outlook Therapeutics' Accumulated Expenses increased by 19.86% in 2017 and then dropped by 28.42% in 2019.
- Over the past 5 years, Outlook Therapeutics' Accumulated Expenses (Yearly) stood at $5.9 million in 2015, then grew by 3.33% to $6.1 million in 2016, then increased by 19.86% to $7.3 million in 2017, then fell by 11.98% to $6.5 million in 2018, then declined by 28.42% to $4.6 million in 2019.